Welcome to article directory Healing Of Nations. Here You can find interesting and useful information on most popular themes.

There are 179 published articles and 488 registered authors in our article directory.

Recent Articles

Yaz Lawsuit News

By admin | Published January 25, 2012

Yaz Lawsuit News 1/23/2012: Until recently, it had appeared self-evident that (nonembolic) arterial thrombosis was the culmination of slow enlargement of the mature atherosclerotic lesion with progressive encroachment into the arterial lumen. This pathobiological construct supported the view that the risk of acute thrombosis was dominated by the sever­ity of arterial stenosis. However, over the past decade, angiographic and patholog­ical data obtained in the coronary arterial bed have challenged this construct. Angiography performed prior to or at the time of acute myocardial infarction has demonstrated that the infarct-related coronary atherosclerotic lesion is frequently not ‘‘critical’’ by standard angiographic criteria. Similarly, pathological examination of culprit lesions has demonstrated that the majority of acute coro­nary events occur with the formation of thrombus at the site of plaques obstruct­ing <50% of the arterial lumen. Taken together with evidence for the impor­tance of plaque disruption in the development of superimposed thrombus (56,65­69), such data have shifted focus from the degree of luminal stenosis to the mor­phological and histological characteristics of the atheromatous plaque that deter­mine its propensity to rupture.

Lending further support to the contribution of inflammatory mechanisms to plaque destabilization, onset of acute thrombosis with or without myocardial necrosis is marked by the production of a number of inflammatory cytokines. In addition, a series of studies have suggested a link between the elabo­ration of inflammatory cytokines and impairment of the ability of smooth muscle cells to maintain the integrity of the fibrous cap (52). Interferon-gamma (IFN-y), a cytokine produced by T-lymphocytes within the atheroma core, decreases the production of collagen by vascular smooth muscle cells (80-82). Smooth muscle cells at the site of plaque rupture or erosion have been found to express high levels of the transplant antigen HLA-DRa, a protein induced only by IFN-y among a wide spectrum of cytokines evaluated

More information on Yaz Lawsuit:

Vascular inflammation may also influence arterial vasomotor function through several possible mechanisms. Increased concentrations of thromboxane A2 and its metabolites produced in acute coronary syndromes (99,100) mediate further platelet aggregation as well as arterial vasoconstriction (101). Leukocytes also produce en- dothelin-1, a potent modulator of vasoconstriction. In addition, certain inflammatory cytokines may increase vascular smooth muscle cell reactivity, as demonstrated in an animal model with IL-1 (102). Finally, inflammatory infiltrates have been documented in the arterial adventitia with vascular nerve involvement and thus have been hypothesized to directly stimulate coronary vasospasm.

In spite of continued advancements in the management of acute ischemic heart disease, morbidity and mortality due to atherosclerotic vascular disease continue to rise globally. Thus, the impetus for improving our strategies for the prevention and management of atherosclerosis has remained strong. In this re­gard, laboratory and experimental research describing key processes in the initia­tion, progression, and destabilization of the atheroma have pointed to novel direc­tions for cardiovascular evaluation and management. In particular, recognition of the role of inflammation in atherothrombosis has directed attention to inflam­matory mediators and indicators as potential targets for risk assessment and for treatment.

Information from other sources on Yaz Lawsuit:

Epidemiological data have established a well-characterized set of vascular risk factors, including advanced age, tobacco use, obesity, diabetes, hypertension, and dyslipidemia. However, up to one-third of first coronary events occur among individuals without these traditional risk factors. Researchers have thus sought to identify inflammatory indicators that might add to these clinical factors for predicting myocardial infarction and stroke. Candidate markers have included several of the cytokines (77,108,109) that promote the recruitment of monocytes in response to endothelial cell dysfunction; intercellular adhesion mol­ecules that mediate the migration of activated monocytes into the subendothelial space; enzymes that might compromise the integrity of the protective fibrous cap, as well as the acute-phase proteins that are produced and released into the systemic circulation in response to inflammatory cytokines.

With systemic levels that are dependent on the rate of de novo hepatic production, CRP levels remain stable over long periods of time in the absence of new stimuli. However, in response to acute tissue injury, infection, or other inflammatory stimuli, CRP levels rise several hundred-fold. As such, CRP and its acute-phase counterpart, serum amyloid A, have been useful in fol­lowing disease activity in chronic inflammatory conditions such as systemic lu­pus, inflammatory bowel disease, and rheumatoid arthritis. Traditional semiquantitative latex agglutination or standard turbidometric methods have been adequate to evaluate such marked elevation of CRP in these disease processes. In contrast, the development of high-sensitivity assays for CRP (hs-CRP) has now enabled detection of CRP within the normal range for healthy individuals. Further, the introduction of high through-put methods with high ana­lytical sensitivity and reproducibility has provided a simple clinical tool to care­fully evaluate the extent of underlying systemic inflammation.

Yaz Lawsuit: More information from other sources related to your search

Antiphospholipid antibodies (APLA) are a heterogeneous group of autoantibod­ies associated with both arterial and venous thrombosis, recurrent pregnancy loss, and thrombocytopenia. They can occur either in association with other auto­immune conditions, most frequently systemic lupus erythematosus (SLE), or in isolation, a condition known as the primary antiphospholipid antibody syndrome. In the research laboratory, many antiphospholipid antibodies (with varying epi­tope specificity) can be identified. However, in clinical practice, the antiphospho­lipid antibodies are divided into two large groups, the lupus anticoagulants and the anticardiolipin antibodies.

Lupus anticoagulants or nonspecific inhibitors interfere with the assembly of procoagulant complexes. In vitro, these antibodies are associated with the pro­longation of phospholipid-dependent blood-clotting times. Characteristically, clotting times return to normal with the addition of exogenous phospholipid. Lu­pus anticoagulants may demonstrate specificity for blood-clotting proteins, in particular prothrombin. However, the mechanism by which they promote throm­bosis is unknown. Lupus anticoagulants are likely associated with a high risk of first and recurrent thrombosis as well as recurrent pregnancy loss.

Yaz Lawsuit: Additional News and Information about Yaz Lawsuit:

APLA are found in about 20% of patients presenting with venous thromboembo­lism (1,2), in about 10% of patients presenting with first ischemic stroke (3), and in approximately 5 to 10% of young people presenting with first myocardial infarction (4). Their prevalence in the unselected population is unknown; reported rates vary widely with the test system used and the population being studied. About 30% of individuals with systemic lupus erythematosus have an APLA (5). Low-titer anticardiolipin antibodies are frequently detected in otherwise well individuals; repeat testing reveals a high rate of spontaneous resolution.

All patients with unexplained venous thrombosis, in particular those with thrombosis in unusual sites (such as the cerebral veins or mesenteric veins), should be screened for an antiphospholipid antibody. Both a lupus and an anticar- diolipin antibody should be sought. Testing should be carried out in accordance with the recommendations of the International Society of Thrombosis and He- mostasis, with appropriate confirmatory assays for suspected lupus anticoagu­lants.

Many questions remain unanswered in patients with antiphospholipid antibodies. First, many patients, particularly those with systemic lupus erythematosus, are screened for the presence of an antiphospholipid antibody despite their never having had an episode of thrombosis. When detected, the clinical importance of the antibody is unknown. As a result, some such patients (who are suspected to have a high risk of first thrombosis) are treated with warfarin with varying INR target ranges, while others are treated with aspirin or other antiplatelet agents, and many receive no antithrombotic prophylaxis. To address the need for routine antithrombotic prophylaxis in this problematic patient population, a large, ran­domized clinical trial is currently being carried out. Within this study, adults and children, with both an antiphospholipid antibody and systemic lupus erythemato­sus, are allocated to long-term warfarin with a target INR of 2.0, or no therapy. The primary outcome measure of the study is the rate of objectively confirmed arterial and venous thrombosis.

Our use of the term or terms Yaz Lawsuit: is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Yaz Lawsuit :visit our site often.

http://www.seedol.com

Posted in Emerging Mass Torts | Tagged , |

Actos Bladder Cancer Top News

By admin | Published January 25, 2012

Actos Bladder Cancer : You probably have already figured out that cystectomy is a surgical procedure performed under anesthesia in a hospital setting. Depending on what kind of bladder reconstruction you have, you may stay in the hospital anywhere from 5 to 14 days. The descriptions included here of medical procedures and treat­ments are of a general nature; your own experience may differ from what is discussed here. With cystectomy, an incision is made through the abdominal wall, so you can expect some mild discomfort at the incision site. The inci­sion will be covered, and you probably won’t be able to shower or get the incision wet for about a week to 10 days. You may have a drain from the incision, a flexible tube with a hollow bulb on the end that you will remove, empty, flush out, and reattach as needed. Your doc­tor will remove the drain (it’s painless) and any stitches or staples in a follow-up visit 10 days or so after your surgery.

Some possible complications include infection, bleeding, blood clots, or intestinal obstruction. You may experience some difficulties with your urinary diversion system. You’ll be asked to wait for a few weeks after surgery before you drive, and your doctors are likely to want you to refrain for several weeks from doing anything that strains the abdominal area, such as pushing and pulling a vacuum cleaner or lifting heavy objects or engaging in any other activity that might damage the scar or even pull the scar tissue apart, thereby risking the formation of a hernia. A her­nia occurs when your surgical scar pulls apart under the skin and allows a part of the underlying bowel to poke forward, creating a noticeable lump. It can interfere with the functioning of your bowel and therefore needs to be fixed, either with an external truss or sup­port, or possibly through another surgical operation.

It’s smarter just to avoid the risk in the first place by not stressing the scar soon after surgery. This is the time to take it easy and when possible allow friends or family to pamper you by helping with chores and housework. Just don’t get too used to having someone bring you the morning newspaper and a cup of coffeel Generally it’s a good idea to talk about this with your doctor and find out what you can and cannot safely do.There are some negative consequences of cystectomy that you should discuss thoroughly with your medical team. As mentioned above, there may be changes in urinary function. These will depend largely on the type of surgery and on whether an artificial bladder has been created. Sometimes while the abdominal tissues are healing after surgery there will be a period of irregular bowel function, during which you will unexpectedly have to deal with diarrhea or constipation.

More information on Actos Bladder Cancer

Occasionally there will be some swelling in one or both legs, due either to fluid retention or the formation of scar tissue around the lymph vessels that drain the legs. Often there will be the presence of an asymptomatic, low-grade chronic urinary tract infection that will be identified upon routine testing. This occurs because of the changed pattern of emptying the new bladder. Usually it causes no problems and doesn’t require active treatment with antibiotics. Other issues also arise. Worries about possible changes in sexual function are common, and very normal. Sexual function often does change after cystectomy That doesn’t mean you can’t have an active, playful, pleasurable sex life with your partner. It does mean that you’ll probably explore innovative strategies as you seek comfortable ways to experience fulfillment.

Men experience more extreme changes in sexual function after surgeiy than women do. Around half the men who undergo cystec­tomy experience nerve damage that leaves them impotent afterwards, a serious lifestyle change that is not only physical but emotional, requiring much thoughtful discussion between you, your partner, and your medical team both before surgery and after. If you are able to have an erection after surgery, you won’t be able to ejaculate, because ’without a prostate, your body is no longer able to produce semen. You’ll find that the physical sensation of orgasm is different from what you are accustomed to. It’s not unpleasant; just different. In general, the younger you are at the time of surgery, the more likely you will be to have erections or to regain over time the capability of having them. There are surgical procedures, such as penile inserts, that can help make sexual activity possible.

For women, a cystectomy includes the removal of the uterus and part of the vaginal wall. What does that mean for you? Well, for one thing, your vagina may be narrower as a result of the surgery. Usually it’s possible to continue to have intercourse, although sometimes there can be some pain involved. Be sure to talk to your doctor if you do experience pain as there are methods of reducing this.

Information from other sources on Actos Bladder Cancer

Most women diagnosed with bladder cancer already have experienced menopause. (Typically, women who receive diagnoses of bladder cancer are older.) For younger women, that may not be the case. The removal of the uterus and pos­sibly of other female organs near the Most women diagnosed bladder brings an abrupt end to the child- with bladder cancer bearing years. It may also set off typical already have experienced menopausal symptoms such as hot flash- menopause. (Typically, es or mood swings if the ovaries have women who receive been removed at surgery (removal of diagnoses of bladder ovaries is unusual). If you find yourself cancer are older.) feeling depressed or blue or uncomfort­able from hot flashes, talk to your doctor. You don’t have to feel that way; there are options available for you to consider.

As is recommended for men, talking with your partner and your medical team about the physical and emotional changes that you may experience after a cystectomy is an important part of the process, one that deserves as much consideration as the more immediate decisions about which treatment options you want to pursue. Keep in mind that cystectomy is a life-preserving weapon against invasive cancer. That doesn’t mean you can’t or shouldn’t consider the possibility of impotence or altered sexual function with your partner, or the inability to carry a child. It does offer the hope that you can celebrate many more years of healthy, loving life with your friends and family. That’s an important thing to remember at a time when life may seem to be serving you big helpings of despair.

Our use of the term or terms Actos Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer visit our site often.

http://www.seedol.com

Posted in Emerging Mass Torts | Tagged , |

Vaginal Lawsuit Petition

By admin | Published January 25, 2012

Vaginal Lawsuit : Oestrogen receptors have been demonstrated in the squamous epithelium of both the proximal and distal urethra.24 Oestrogen has been shown to improve the maturation index of urethral squamous epitheLium.25It has been suggested that oestrogen increases urethral closure pressure and improves pressure transmission to the proximal urethra, both of which promote continence. Epidemiological studies have implicated oestrogen deficiency in the aetiology of lower urinary tract symptoms. Seventy percent of women relate the onset of urinary incontinence to their final menstrual period.2 Lower urinary tract symptoms have been shown to be common in postmenopausal women attending a menopause clinic, with 20% complaining of severe urgency and almost 50% complaining of stress incontinence.

There is, however, conflicting evidence regarding the role of oestrogen withdrawal at the time of the menopause. Some studies have shown a peak incidence in perimenopausal women36‘37 whilst other evidence suggests that many women develop incontinence at least 10 years prior to the cessation of menstruation, with significantly more premenopausal women than postmenopausal women being affected.

For more information on Vaginal Lawsuit follow us on our RSS Feeds.

Urinary tract infection is also a common cause of urinary symptoms in women of all ages. This is a particular problem in the elderly with a reported incidence of 20% in the community and over 50% in institutionalized patients.39‘40 Pathophysiological changes, such as impairment of bladder emptying, poor perineal hygiene and both faecal and urinary incontinence, may partly account for the high prevalence observed. In addition, as previously described, changes in the vaginal flora due to oestrogen depletion lead to colonization with Gramnegative bacilli, which, as well as causing local irritative symptoms, also act as uropathogens. These microbiological changes may be reversed with oestrogen replacement following the menopause, offering a rationale for treatment and prophylaxis.

Information from other sources on Vaginal Lawsuit

Oestrogen preparations have been used for many years in the treatment of urinary incontinence,41‘42 although their precise role remains controversial. Many of the studies performed have been uncontrolled observational series examining the use of a wide range of different preparations, doses and routes of administration. The inconsistent use of progestogens to provide endometrial protection is a further confounding factor making interpretation of the results difficult.

Our use of the term or terms Vaginal Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Vaginal Lawsuit visit our site often.

.

Posted in Emerging Mass Torts | Tagged , |

Actos Side Effects Info

By admin | Published January 25, 2012

Actos Side Effects : More information on Actos Side Effects

After the initial shock of being given a new diagnosis of cancer, a flood of emotions follow with fear and anxiety being foremost. Questions fill your mind:

How serious is it?

Can 1 be cured?

Am I going to die?

Will I suffer?

What treatments are available?

Can 1 do anything to improve my odds?

What side effects will occur from the treatments?

Will I lose time from work?

Will my insurance cover the cost?

Will I be disfigured?

Will my spouse and family be supportive?

Do 1 have a good doctor?

Bladder cancer, or any serious potentially life threatening illness is generally alien to most individuals. Suddenly, lives are changed and a new reality must be dealt with. Becoming a “patient” or worse “a cancer patient” is not only threatening, but a dreaded proposition. Cancer patients are not happy with the loss of autonomy, the invasion of privacy, the discomfort inflicted upon them and the demands on their time and quality of life. As a patient, being thrust into this altered identity, it is essential to seek out the information you need. Having a fundamental base of knowledge is a must when facing the issues and treatment decisions which lie ahead. In the following pages, together we will explore bladder cancer, a disease which is totally foreign to most of us until the diagnosis is made. I have chosen to present the information in a question and answer format, written in a conversational tone, as if I were having an extended consultation with one of my patients. The questions are typical of what individuals have asked over the years. 1 have covered the key issues and decisions the individual with bladder cancer may face. The answers are to the point and cover the essentials required to make an informed decision for most individuals. For others, a more detailed resource may be required. For helpful sources of additional information see the Appendix.

Each individual’s situation is unique. Decisions on treatment may be modified based on the patient’s preferences and values and altered by other considerations such as age and coexisting conditions. By becoming an individual knowledgeable of bladder cancer, you will be prepared to fully partner with your physician for your best possible outcome. To your companions and family members, this book will serve to answer the many questions and doubts that may arise. Having your loved ones informed and supportive is a big plus for the individual facing this new challenge.

The book is written in a logical sequence starting with finding a qualified urologist to the basics on bladder cancer, its assessment and treatment. At the end of the book, you will find chapters on complementary medicine, advance care planning, and hospice care. The book can be read in sequence or each chapter can serve as a resource covering the basics of the topic. It is my hope this book will help clarify the many issues and options individuals must face with bladder cancer. For family members, significant others and concerned friends, this resource should help improve your understanding and thus your ability to assist your loved one.

 

Information from other sources on Actos Side Effects

Understanding bladder cancer is a tremendous first step that will assist you in your treatment. Having a qualified urologist administer the actual treatments and care for you is essential for the best possible outcome. In the following chapter, we will explore what you need to know to assure you have the right urologist.

BESIDES LEARNING ABOUT MY DISEASE, WHAT IS MY MOST IMPORTANT FIRST STEP?

Make sure you have an excellent urologist supervising your care. A urologist is a surgical specialist trained to care for conditions involving the male and female urinary tracts and the male reproductive system. The bladder is part of the urinary system, and a urologist is trained to care for problems involving it, including cancer.

IS IT IMPORTANT TO HAVE A BOARD CERTIFIED UROLOGIST?

A urologist board certified by The American Board of Urology has gone through an accredited urology training program (generally a four year program), following two years of internship and residency in surgery after four years of medical school. The urologist must be in practice after training and provide a detailed list of surgeries, including complications, over a twelve month period. The doctor will then take a two day oral and written test covering a wide spectrum of urology. If he passes, he is certified for a period of ten years. At the end of the ten year period, he must recertify to maintain his board status. Recertification entails a three month surgical and procedure log and a written test as well as reference letters from those in a position to judge the practicing urologist’s work. Any malpractice or judgments are also reviewed. Although being board certified does not guarantee you have an excellent urologist, it demonstrates that he has the fund of knowledge to practice urology competently. Even though board certification is voluntary, in today’s competitive environment more and more hospitals and insurance plans are requiring their specialists to be certified.

HOW CAN I TELL IF MY UROLOGIST IS BOARD CERTIFIED?

The urologist has worked hard to obtain board certification. The certificate from The American Board of Urology is often displayed openly in his office. If you do not see it, you can simply ask him or you can call 1-866-275-2267 or use this web site: www.certified doctor.org

SHOULD I TRY TO FIND A UROLOGIST WHO HAS BEEN IN PRACTICE FOR YEARS OR A NEWLY TRAINED ONE?

Surgery is a skill which can only be mastered with experience. The saying “practice makes perfect” definitely pertains to surgery. Although a urology training program offers the new physician years of training, his surgical skills will continue to improve with further experience. However, each individual physician has his own innate skills. Some more quickly learn and are simply better at the technical craft of surgery than others. For the most part, urologists finishing an accredited urology program have the training and skill set required to care for patients with bladder cancer.

Experience also counts. As a physician practices the art of medicine, his depth of knowledge and ability to treat grows. Ask your physician how long he has been treating patients with bladder cancer. If you require major surgery ask how many he has performed and if his complication rate matches what is expected.

Physicians by and large do improve as they practice, and all physicians are required to show that they are continuing to learn by partaking in continuing medical education, a requirement to remain licensed. Most physicians are compulsive in their medical practice and care deeply in the care they deliver. They continually strive to improve.

Some physicians may become “burned out” over the years as they continue to face the pressures of a busy medical practice. Similarly, towards the end of a surgeon’s career, technical skills may slip due to aging. New urologists are trained in the latest techniques and are familiar with recent medical literature, but may lack practical experience. In the end, recommendations from others and reputation may be your best guide to finding a qualified physician.

WHAT QUALITIES SHOULD MY UROLOGIST HAVE?

Ideally, you should have a competent, technically skilled surgeon who is also approachable and compassionate. You should be able to freely ask questions pertaining to your disease and treatment. Your physician should answer your questions forthrightly. Although some patients prefer a surgeon who will take over all aspects of care with no questions asked, most prefer in depth explanations, especially when alternatives exist and risks are involved.

Your urologist must be an individual who takes your concerns, priorities and values seriously. Your urologist should be a good communicator. It is his responsibility to keep you fully informed of your progress, make you aware immediately if things are not going well, and educate you fully in treatment alternatives. Your specific values should be incorporated into the decision process if alternatives are available. Even if your urologist makes a recommendation and you choose an alternative course (unless you are putting yourself in extreme jeopardy), he should honor your choice and continue his care of you. Becoming an educated patient will make your decision making process easier. Granted, your physician should provide you with the basics, however having time to review and digest the material will allow you to fully understand and accept your treatment regimen, providing you with peace of mind.

Beware of the physician who bombards you with statistics and studies and leaves the decision making to you. After all, you are not a physician and don’t have the practical hands on experience he does. Your physician should provide the facts and the statistics, guide you through the information, and make treatment recommendations based on your preferences.

You may find yourself emotionally distraught and overwhelmed. Having a physician on your side is invaluable. You should be able to trust your physician. Complete honesty on the part of your doctor in his care of you is a must. From the doctor’s point of view, trust is also a necessity. Physicians have an extremely difficult time dealing with individuals who do not trust them. Without trust, the physician patient relationship is extremely hindered.

Lastly, your urologist should be compassionate. Having cancer is tough enough, you shouldn’t have to deal with a rude or arrogant physician. Your urologist should be supportive at all times. He should treat you as an individual and not just as “another cancer patient.” People with bladder cancer will require long term follow up and care. Having a compassionate individual to work with will make a tremendous difference

HOW DO I FIND A GOOD BOARD CERTIFIED UROLOGIST?

A good starting point is your primary care physician. He will generally have a number of specialists to whom he generally refers his urology patients. If the primary care physician has been working with these urologists, he should have an appreciation of their skills and temperament. However, this does not mean he is referring you necessarily to the best available urologist in your area. His choices may be limited by insurance or hospital networks. An excellent source of information would be nurses who work in the operating room, recovery room or on the surgical floor where the urologist does his surgery. Asking friends or other individuals who have had experience with the urologist can also prove useful. After a little digging, you can often quickly learn what type of reputation the urologist has in the community. Generally, if an established urologist has a “good reputation” this is an indication that he has pleased many individuals with his care.

SHOULD I CHECK TO SEE HOW MANY TIMES MY UROLOGIST HAS BEEN SUED?

Given the litigious society we live in, most physicians can face at least one malpractice lawsuit during their careers. In urology, two of the most common causes of litigation would be a surgical mishap leading to a complication, or failure to diagnose cancer in a timely fashion.

Medicine is based on science, but also is an “art.” Individuals do not walk into their physicians offices with a diagnosis and treatment plan always readily apparent. Even the best intentioned, thorough physician will make mistakes. Most of these errors do not result in harm. On occasion they do, and a law suit may follow. If a physician develops a good working relationship with a patient, these bad outcomes more often than not are acknowledged and accepted without legal entanglement. Competent, busy physicians may be dealing with a higher mix of complicated patients, leading to a higher number of potential suits. Physicians who have poor “bed side manner” may find themselves dealing with more suits. If a physician has an inordinate number of suits, “red flags” should go up, as competency may be an issue.

For those individuals who wish to check out the malpractice history of their physician, you may request an inquiry from the National Practitioners Data Bank at: 1-800-767-6732 or check the web site: www.npdb-hipdb.com

Our use of the term or terms Actos Side Effects is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Side Effects visit our site often.

http://www.seedol.com

Posted in Emerging Mass Torts | Tagged , |

Trans Vaginal Mesh Lawsuit Data

By admin | Published January 25, 2012

Trans Vaginal Mesh Lawsuit : Fistulae are rare in England and are usually secondary to gynaecological surgery, maLignancy or radiotherapy. A fistula is an abnormal connection between two epithelial surfaces. Surgical procedures associated with vesicovaginal fistula. Obstetric fistulae are much commoner in the developing world and are a frequent reason why women are cast out of their homes and communities and abandoned. Urethrovaginal and ureterovaginal fistulae are much less common than vesicovaginal fistulae. In the developed world they are unusual causes of urinary incontinence (UI). Once again, the most common cause of these fistuale in the developing world is obstetric trauma due to ischaemic necrosis; in developed countries the most common cause is surgery. Anterior repair, vaginal hysterectomy and urethral diverticulectomy have all been associated with an increased risk of urethral fistula formation.

USI, as opposed to the patient symptom ‘stress urinary incontinence’ (SUI), is only diagnosed after performing urodynamics and is the involuntary leakage of urine per urethram during periods of raised intraabdominal pressure, in the absence of a detrusor contraction. Normal urethral function maintains a positive urethral closure pressure in the presence of raised intraabdominal pressure, although DO may overcome it. An incompetent urethra allows leakage of urine, even in the absence of a detrusor contraction. Damage to the pubo- urethral ligaments and the levator ani muscles (secondary to pregnancy, childbirth, obesity, radical pelvic surgery, abdominopelvic mass or chronic cough, and possibly exacerbated by inherited weak collagen) may allow bladder- neck hypermobility and descent of the bladder neck and proximal urethra, so that they are no Longer within the intraabdominal pressure zone.

For more information on Trans Vaginal Mesh Lawsuit follow us on our RSS Feeds.

demonstrated denervation of the intrinsic and extrinsic sphincter mechanisms.5,6This is known as ‘intrinsic sphincter deficiency’, where the hermetic closure properties of the proximal urethra are lost and USI may be the result. From September 2004 the first drug treatment for SUI, duloxetine, will be available. It is essential to be sure of the diagnosis by excluding DO (see Chapter 6) – a minority of patients opting for a surgical treatment develop irritative symptoms of urgency and frequency or voiding difficulty postoperativeLy, and pre­existing symptoms are likely to be exacerbated.

DO is a urodynamic observation characterized by involuntary detrusor contractions that may be spontaneous or provoked. The contractions occur during the filling phase. Phasic DO is defined by a characteristic waveform that mimics the normal voiding cycle, but which does not inevitably lead to UI. Terminal DO is defined as a single involuntary detrusor contraction at cystometric capacity, which cannot be suppressed, and leads to incontinence – usually complete – and catastrophic bladder emptying.7 Provoked DO is the association of a detrusor contraction with either a physical provocation to the bladder, such as coughing and standing, or a psychological provocation such as hearing running water.

Information from other sources on Trans Vaginal Mesh Lawsuit

Symptomatically, these patients are similar to, and often indistinguishable from, patients with DO. Sometimes, however, low compliance may be associated with a fast bladder-filling rate. Low compliance is seen less often at Patients with DO are often indistinguishable from patients with low compliance; however, low compliance may be associated with a fast bladder-filling rate and is seen less often at physiological filling rates. The incidence of DO increases with age, and urge incontinence is the commonest symptom of incontinence in people aged over 60 years8 and the elderly.9 Urodynamic assessment is required to make an accurate diagnosis, as women usually present with multiple symptoms, most commonly a syndrome of frequency, urgency and nocturia. The pathophysiology of DO is poorly understood and an underlying cause is rarely found, leading to the term idiopathic DO. Detrusor overactivity and USI can coexist as mixed incontinence and DO can arise de novo after incontinence surgery.

Our use of the term or terms Trans Vaginal Mesh Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Trans Vaginal Mesh Lawsuit visit our site often.

Trans Vaginal Mesh Lawsuit

Posted in Emerging Mass Torts | Tagged , |

Actos and Bladder Cancer Bulletin

By admin | Published January 25, 2012

Actos and Bladder Cancer : BC is a disease of the environment and age . Populations are increasing in number, and they are growing old as well., . Since more people are living longer, more are at potential risk. Furthermore, the changing environments in developed and developing countries are causing more carcinogen concentration than can be associated to genesis of BC. Several carcinogens have been correlated to BC carcinogenesis.However, it has been proposed that other environmental factors could affect the incidence on urothelial tumors. In fact, as for many other cancers, molecular researchers try to establish genetic alterations linked to carcinogenesis that could justify genetic predisposition.

Cancer is a major public health problem. At the end of the twentieth century, more than 930,000 people died of cancer every year in 15 member countries of the European Union (EU) (Coleman et al. 2003). Using population projections, if the age-specific death rates remain constant, the absolute number of cancer deaths in 2015 will increase to 140,500 (Boyle and Ferlay 2005). BC is a worldwide health problem. In 2006 in Europe, there were an estimated 104,400 incident cases of BC

 

More information on Actos and Bladder Cancer

diagnosed (82,800 in men and 21,600 in women) that represent a 6.6% of the total cancers in men and 2.1% in women. The estimated ratio by gender was 3.8:1, respectively. In men BC was the fourth most common cancer. Bladder cancer repre­sents a 4.1% of total deaths for cancer in men and 1.8% of total deaths in women (Ferlay et al. 2007). In the EU overall (27 countries), BC mortality rates were stable up to early 1990s, and declined, thereafter, by 16% in men and 12% in women, to reach values of 6 and 1.3/100,000, respectively, in the early years of the present decade. The only countries without declining mortality are Croatia and Poland in both sexes, Romania in men, and Denmark in women. This documented and quanti­fied reduction in BC mortality seems related to decrease in tobacco smoking, while its relationship with other risk factors remains controversial (Ferlay et al. 2008).In the United States, it is estimated that about 1.4 million new cases of cancer was diagnosed in 2008. Cancers of the prostate and breast are the most frequently diagnosed cancers in men and women, respectively, followed by lung and colorec­tal cancers in both men and in women. The fourth most common among men is the urinary BC. The 5-year relative survival rate for BC is 81% among whites and 65% among African-Americans (AAs) (taking the normal life expectancy into consider­ation) with an absolute difference of 16%. The survival rates for BC combined with certain site-specific cancer have improved significantly since the 1970s—being 74% during 1975-1977, 78% during 1984-1986, and 81% during 1996-2003.

 

Information from other sources on Actos and Bladder Cancer

Contrary to this data, the prevalence of BC among Native Americans/Alaskan Natives (NA/AN) is generally considered to be low. Despite this low incidence, NA/AN men and women seem to be at relatively greater risk of dying from BC, once it has been diagnosed (Watson and Sidor 2008).Tobacco use is a major preventable cause of death, and especially involved in BC carcinogenesis. The year 2004 marks the anniversary of the release of the first Surgeon General’s report on Tobacco and Health, which initiated a decline in per capita cigarette consumption in the United States (Jemal et al. 2008).

In Egypt, where BC has always been related to bilharziasis, a significance decline of the relative frequency of BC was observed from 27.63% in the old series to 11.7% in the recent series. Bilharzias association dropped from 82.4% to 55.3% and there was a significant increase of transitional cell carcinoma from 16% to 65%, while squamous cell carcinoma was less frequent—from 76% to 28%. Intimately related to this, there was an increase in the median age of patients from 47 to 60 years. The decline in the frequency of BC is related to a decline in bilhar- zias egg positivity in the specimen, and this suggests a better control of the endemic disease in rural population. This trend of less association with bilharzias has changed the clinical and pathological characteristics of BC diagnosed, with signifi­cant predominance of transitional cell carcinoma and an increase in the age of patients, a pattern more similar to that in western series (Gouda et al. 2007).

The incidence and mortality rates associated with BC vary by country, ethnicity, gender, and age. For indeterminate causes, the AAs have only half the risk of white European Americans, but overall, the survival seems to be worse among the primer group. The higher incidence in European Americans is limited to superficial tumors, both groups having a similar risk of invasive tumor (Kirkali et al. 2005).

 

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com

Posted in Emerging Mass Torts | Tagged , |

Actos Warning Information

By admin | Published January 25, 2012

Actos Warning: Occupational exposure has been considered the second most important risk factor for BC. Work related cases account for a 20%-25% of all BC cases in several series. The cause relation between chemical exposure and BC was reported more than a century ago among workers employed in the manufacture of dyestuffs containing aromatic amines (Pelucchi et al. 2006). Rehn reported in 1895 and 1896 a relationship between chemical exposure and BC among workers involved in the manufacture of coal tar derived magenta and auramine dyes, and 47 years later Hueper and Wolf demonstrated that 2-naphthylamines was the substance respon­sible for BC risk associated with chemical exposure (Johansson and Cohen 1997).The substances involved in chemical exposure had been benzene derivatives and arylamines (2-naphthylamine, 4-ABP, 4,4′-methylenedianiline and o-toluidine).

 

More information on Actos Warning

One study of municipal distribution of BC in Spain detected 34,281 BC deaths registered between 1989 and 1998. They could observe that determinate zones exhibited a higher risk than others, these being provinces of Cadiz, Seville, Huelva, Barcelona, and Almeria. The municipal mortality patterns suggested that the industrial and mining activity in the Provinces of Seville and Huelva could be associated with higher BC mortality in these provinces. The mortality pattern assessed in two different areas of the Province of Barcelona, which is only observable in women, might be related to the textile industry traditionally situated in these areas (Lopez-Abente et al. 2006).The trend to decrease BC due to occupational exposure was reported in a pooled analysis of 11 case-control studies on BC conducted in European countries between 1976 and 1996. This analysis included 3346 male cases and 6840 male controls. Thirty-one occupations showed increase risk for BC and these occupations were grouped as metal workers, textile workers, painters, miners, and transport opera­tors. Higher odd ratios were observed on those people with duration of employment more than 25 years. However, the author concluded that the ratio of BCs caused by occupational exposure was lower than those identified one year ago and that the exposure to occupational carcinogens had been reduced in the European Union.

 

Information from other sources on Actos Warning

This would likely be due to the improvement in working conditions and the reduction of exposure, particularly, to aromatic amines in work. Currently, employ­ments that relate more to BC risk are those in metal sector, machinists, transport operators, and miners (Kogevinas et al. 2003).In addition to the analysis on men, a pooled analysis of 11 case-control studies in BC conducted in Western Europe showed that the rates of BC due to occupa­tional exposure had been reduced in women, with only a 8% of BC in women attributable to occupational carcinogens (Mannetje et al. 1999). Although in devel­oped countries strict regulatory controls may have contributed to a decreased bur­den of exposure to bladder carcinogens in the workplace, the situation is less apparent in developing countries.As in BC, in general, occupational case is more frequent in men than in women, although, an increased risk among women has been documented in several studies, including those employed in the rubber industry and, more recently, in healthcare settings. In a case-control study conducted in Iowa, female teachers, domestic ser­vice employees, and workers in laundering and dry-cleaning business had elevated risk of BC. Other gender and racial differences had been documented in occupa­tional BC. In this way, in a recent mortality study in the United States, the mortality ratios for AA men and women and Latino males in various occupations were found to be increased compared with workers of the same gender and ethnic-racial group (Delclos and Lerner 2008).

 

Our use of the term or terms Actos Warning is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Warning visit our site often.

http://www.seedol.com

Posted in Emerging Mass Torts | Tagged , |

Mesothelioma Cancer Information

By admin | Published January 25, 2012

Mesothelioma Cancer : After performing the physical exam and taking a his­tory that concentrates on whether you have developed shortness of breath or pain, the doctor will order a chest x-ray. Based on what is found, the doctor will determine what other tests you will need. The doctor may also order blood work. When a tumor or fluid is found, the doctor will need to perform a procedure that mil obtain cells for the physicians to study to determine whether this is a cancer or not. This can be done by performing a biopsy of the mass or by tapping fluid (inserting a needle and drawing out fluid) from the chest or belly cavity and then analyzing the cells that come with the fluid. The analysis of cells from fluid is called cytology. Although an x-ray or scan may provide useful information about the size, shape, and location of a tumor or fluid and may alert your doctor to the possibility of a cancer, an actual diagnosis of mesothelioma cannot be made without a biopsy, or undeniable evidence of cells in the fluid that have the characteristics of a mesothelioma. Mesothelioma Cancer

For more information on Mesothelioma Cancer follow us on our RSS Feeds.

There are no specific blood tests that can tell your doctor you have mesothelioma. Certain blood cell values may be abnormal when a patient has mesothelioma, but these are nonspecific (that is, they do not definitively tell the doctor that it is mesothelioma or another type of cancer or a benign condition). The white blood cell count (cells that fight infection) may be elevated and/or the platelet count (cells that help the clotting system) maybe elevated above normal values.

The liquid part of blood (serum) is partially comprised of dissolved proteins. Currendy, there are no specific proteins in the serum that can tell your doctor you have asbestosis or mesothelioma. Proteins that are spe­cific to a certain disease are called biomarkers. There is great interest in the discovery of these biomarkers, which may represent unique proteins from the tumor that appear early in the disease and increase as the dis­ease progresses. Ask your physician whether any of these markers are under study or whether any have been approved by the FDA for the study of mesothe­lioma. These markers include soluble mesothelin related protein (SMRP) and osteopontin. Mesothelioma Cancer

Information from other sources on Mesothelioma Cancer

The results of the chest x-ray will usually prompt the doctor to order a CAT or CT scan (computerized axial tomography scan) of the chest and abdomen. These scans provide a three-dimensional view of the area of the body that the physician is interested in. CT scans have a better ability to show how much solid mass is present and how much fluid contributes to the picture. They also give a much better anatomic picture so your doctor can see how any masses relate to the lung, heart, diaphragm (the muscle that helps you breathe), and blood vessels in the chest or abdomen. CT scans do not tell the doctor what type of tumor it is or whether the disease has invaded other structures, but they do give a very good idea of whether your disease can be classified as early with minimal disease (Stage I), later with moderate amount of disease (Stage II), or advanced with a large amount of disease (Stages III and IV). (We will discuss the concept of staging in more detail later on.) In mesothelioma, a CT scan is not very good for showing whether your lymph nodes (the round structures in certain positions in the chest and abdomen that drain the lung and intestines and act as filters and sites for immune responses) are involved. The reason it does not show this well is that the pleura can be thickened in areas where the lymph nodes are, and this lumpy, bumpy thickening can be confused with lymph nodes or can hide lymph nodes.

Our use of the term or terms Mesothelioma Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Mesothelioma Cancer visit our site often.

Mesothelioma Cancer

Posted in Emerging Mass Torts | Tagged , |

Actos and Bladder Cancer Resources

By admin | Published January 25, 2012

Actos and Bladder Cancer: NAVIGATING APPOINTMENTS

Calls initially made to a urology office or clinic are triaged by the scheduling staff who are trained to inquire about the current stage of your workup for your bladder cancer. It is most helpful to have a working knowledge of the tests and diagnoses you have already been given to best facilitate this process. The staff will schedule your initial appoint­ment and mail you all necessary instructions before your appointment. After your initial appointment, subsequent appointments may often be arranged by the individual team members’ staff over the phone. If at the initial ap­pointment it is determined you should have a consultation with another team member (e.g., medical oncologist or radiation oncologist), that appointment is often arranged for you on die day of your initial consultation with the uro- logic oncologist-—-before you leave the clinic if you choose. Therefore having your schedule available allows you to ef­ficiently make these arrangements without conflict.

 

More information on Actos and Bladder Cancer

FINANCIAL IMPLICATIONS OF TREATMENT/INSURANCE CLEARANCE

You probably never planned on getting diagnosed with bladder cancer. There is no convenient time to get this dis­ease, and the diagnosis alone can be difficult to manage. You will need to take time off from work and other duties for your surgery and possibly for other treatment after­ward. It is helpful then to “get your ducks in a row” early on. Finding out how much sick leave you have, short-term disability coverage, copayment information, prescription coverage, and other medical expense issues is helpful to plan for die changes this will have on your budget. Your insurance company may require referrals to be obtained to see certain specialists, to get tests done, to get surgery au­thorized, as well as to obtain other treatments. If you need help with these things, ask for a social worker to assist you. Financial coordinators are available in the clinic. They will work with you to help you navigate the financial aspect of this process.

Some treatments may be recommended that involve par­ticipation in a clinical trial. Usually, a research nurse will as­sist you with navigating the financial aspects of this line of therapy and can provide much of that information for you.

 

Information from other sources on Actos and Bladder Cancer

Financial support services are not well advertised. It re­quires you to take the initiative to ask about them rather than waiting for someone to tell you about them. Be asser­tive and do this for yourself That’s why these programs ex­ist. Money is the primary reason family members get into arguments. Avoid this up front by discussing the issue and planning a budget. Be proactive in asking to meet with the social worker to discuss what support services are available for you as well.

 

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

Actos and Bladder Cancer

Posted in Emerging Mass Torts | Tagged , |

Actos Lawsuit Legal Scoop

By admin | Published January 25, 2012

Actos Lawsuit: To understand cancer, we must first understand nor­mal functioning of the body. The body is made up of billions of cells. Each organ of the body is made up of several different types of specialized cells. For example, the liver has cells that filter toxins from the blood, and the brain has nerve cells (called neurons) that are able to conduct electrical signals. Perhaps the most familiar cells are skin cells. Every flake of dry skin is made of millions of cells that are constantly dying and being replaced with new cells. The growth of new cells is care­fully balanced to occur at the same rate as the death of old cells. Your body has many mechanisms in place to regulate the timing of the birth and death of cells. Unfortunately, if one of these mechanisms malfunc­tions, the careful balance can be disrupted. Environ­mental toxins such as cigarette smoke, chemicals, and radiation can damage DNA and can disrupt these control mechanisms. A tumor may develop when new cells are created faster than old cells die. Tumors can be either benign or malignant. A benign tumor is an overgrowth of cells that is unchecked by the body’s normal mechanisms; thus, it will keep getting bigger. It is called benign because it does not cause you illness. Some benign tumors can get to be so large that they do cause problems, especially if they are in a confined space, such as your skull. A malignant tumor is also an overgrowth of cells.

You can live without a bladder. However, you still need something that can perform the two basic func­tions of the bladder: storing and emptying of urine. Physicians have come up with many ways over the years to accomplish these tasks, many of which are still used today. The simplest alternative is to place drainage tubes into the kidneys that come out through the skin and connect to bags on the abdomen. These tubes are known as nephrostomy tubes. Nephrostomy tubes are typically inserted into a person in the X-ray department by an interventional radiologist who uses some light sedation. For the patient, the bag provides an easy way to store urine and can be drained several times a day when convenient by opening a small valve on the bag.

For more information on Actos Lawsuit follow us on our RSS Feeds.

To provide a good long-term solution, surgeons most commonly use a portion of the small bowel to act as the new bladder. The identified piece of small bowel is removed from the main portion and is fashioned for its new use (see Question 79 for details). The urine that collects within this piece of bowel will ultimately be drained in one of three ways. First, the bowel can simply be left open at the skin for the urine to drain passively out into a bag that is attached to the abdomen. This type of drainage is known as a conduit, and the opening onto the skin is called a urostomy. Urine collects in the bag, which is then drained into a toilet several times each day. Second, the bowel can be sewn into a rough sphere con­nected to the skin by only a small, long channel. This channel prevents urine from leaking out but easily accommodates a small catheter. This is called a conti­nent urinary diversion. With this type of diversion, you must pass a catheter into the new bladder several times a day to drain the urine. This allows you to live without an ostomy bag, but for some patients, passing the catheter several times a day may be difficult or impossible. Third, the new bladder can be directly reattached to the urethra (called an orthotopic neobladder).

Information from other sources on Actos Lawsuit

Bladder cancer is a malignant overgrowth of the cells of the bladder. Most commonly, the growth occurs in cells that are in the urothelium. The lining of most hollow spaces in the body is made of epithelial cells. The lining of the inside of your cheek, for instance, is an epithelial cell lining. Also, the lining of your stomach, bowels, gallbladder, and—you guessed it—the bladder is made of epithelial cells. Each organ has its own subset of epithelial cells. In the bladder, the lining cells are called transitional epithelial cells. The cancer that grows from these cells is then called transitional cell cancer; 90% to 95% of all bladder cancers are of this type. If the cancer grows from a different type of cell in the bladder, it is given a different name. Other types of uncommon cancers in the bladder include squamous cell carcinoma and adenocarcinoma.

It is also possible that cancer in the bladder did not begin there but spread to the bladder from somewhere else. The bladder is an uncommon place for other tumors to “seed” (or metastasize), but it does occasionally occur. Although metastases are uncommon, tumors can occa­sionally grow directly into the bladder from an adjacent organ, such as the prostate, colon, rectum, or cervix. Bladder cancer is the fourth most common type of cancer in men and the eighth most common in women. The American Cancer Society estimated that in 2009, there would be about 70,980 new cases of bladder cancer diagnosed in the United States. In 2009, 14,330 deaths were expected from bladder cancer. In spite of the increased incidence of bladder cancer over the years, the rate of people dying from bladder cancer has decreased over the past 20 years.

Our use of the term or terms Actos Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Lawsuit visit our site often.

Actos Lawsuit

Posted in Emerging Mass Torts | Tagged , |